Novo Nordisk A/S NVO New York Stock Exchange

Novo Nordisk A/S (NVO) reported moderate year-over-year revenue growth of +6.2% through 2025-12 (TTM revenue vs prior-year TTM). Net income showed solid earnings growth of +1.2% YoY, reaching $26.7B in the latest quarter. The net profit margin is 34%, which is exceptional. The company has maintained profitability in all 4 quarters. The gross margin is 81% (high), down 3.7pp vs the prior year. With a $175B market cap, MOAT composite score of 85/100 (strong competitive position).

Criteria proven by this page:

• GROWTH (90/100, Partial) — growth is present but not consistently above 5% across both metrics
• PAST (100/100, Pass) — proving consistent earnings. Looking at the full 41-year annual history, the company was profitable in 41 of 41 years — a perfect long-term track record
• INCOME (100/100, Pass) — proves strong profitability and pricing power
• MOAT (85/100, Pass) — strong gross margins and market scale prove a durable competitive advantage

Overall SharesGrow Score: 81/100 with 5/7 criteria passed.